Sotera Health Company Common Stock
Here’s whether Sotera Health Company Common Stock (SHC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +55.4%. Concerns: 50-day MA is falling (-3.55% over 10 days); RSI 88 — overbought, elevated pullback risk; 3-month momentum negative (-15.0%); declining volume on rally — weak conviction (0.78x 30d avg). Currently 17.9% off its 52-week high. Score: +0/7.
SHC is in a confirmed uptrend, trading above both its 50-day ($15.39) and 200-day ($15.72) moving averages. With an RSI of 87.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +55.4% compares to +35.1% for SPY (beat the market by 20.3%).